RxDoctor Payments Data

Janise Whitesell, MD

Family Medicine · Saint Marys, GANPI 1154322899

Payments from drug & device makers

$10,127in general payments, 2019–2025

Across 574 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$985
  • GSK$963
  • AstraZeneca$960
  • Lilly USA, LLC$653
  • Amgen$598
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$10,02699%
  • Education$1011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,127 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$162,807
Medicare patients
281
Services billed
3,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$107,181
OzempicSemaglutide72$89,547
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$75,872
EliquisApixaban77$60,563
JanuviaSitagliptin Phosphate41$41,268
TrulicityDulaglutide24$38,870
JardianceEmpagliflozin33$25,948
Tresiba Flextouch U-100Insulin Degludec40$24,727
FarxigaDapagliflozin Propanediol21$20,080
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$19,085
JanumetSitagliptin Phos/Metformin Hcl12$16,539
Breo ElliptaFluticasone/Vilanterol20$15,086
Victoza 3-PakLiraglutide11$10,276
MyrbetriqMirabegron18$9,159
EntrestoSacubitril/Valsartan15$9,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$653$146,05298 claims
GSKTrelegy Ellipta, Breo Ellipta$963$90,95995 claims
Novo NordiskOzempic$1,023$89,54772 claims
MerckJanuvia, Janumet, Janumet Xr$195$65,04766 claims
PfizerEliquis$339$60,56377 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$960$43,84550 claims
Boehringer IngelheimJardiance$94$25,94833 claims
Astellas Pharma US IncMyrbetriq$408$9,15918 claims
NovartisEntresto$486$9,04915 claims
AbbVieSynthroid$985$1,92539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Saint Marys

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →